CCR4 antagonists have potential as combinatorial agents for immuno-oncology therapies

28 May 2020 (Last Updated May 28th, 2020 10:16)

Despite chemotherapies historically standing as the primary oncological treatment approach, the arrival of immunotherapies has shifted the treatment paradigm in a variety of cancers, due to their method of increasing the immune system's anti-tumour ability with fewer side effects.

Currently, a significant strategy in immuno-oncology development is to bring combinations to the market in order to improve the efficacy of immuno-oncology products. Read more here.